Streetbeat News

LOBEF

Lobe Sciences Ltd

CEO

Rahim Rajwani

Industry

Research and Development in Biotechnology

Open

0.01

Mkt cap

257K

Volume

High

0.01

P/E Ratio

-0.07

52-wk high

0.02

Low

0.00

Div yield

N/A

52-wk low

0.00

The Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored a Psychedelic Science conference in Denver, attracting over 12,000 attendees. New York Mets owner Steve Cohen announced a $5 million grant for MAPS’ ongoing clinical studies toward FDA approval of MDMA-assisted therapy for PTSD. Toms Shoes founder Blake Mycoskie pledged to donate and invest $100 million in organizations and projects advancing psychedelic-assisted therapies. SEMRush (NYSE:SEMR) analysis revealed a shift in America's consciousness towards psychedelics and cannabis. Several companies received regulatory approvals and patents, and announced partnerships and financial results.

Portfolio Pulse from Lara Goldstein

July 04, 2023 | 2:21 pm

Lobe Sciences Ltd. (OTCQB:LOBEF) has started its Phase 1 clinical study on proprietary psilocin analog L-130, aimed at treating Chronic Cluster Headaches (CCH). The study is being conducted in Jordan under the country’s FDA authority. The results of the study, expected to be completed in Q3 2021, will be used to determine L-130 dose levels for an upcoming Phase 2a study in CCH.

Portfolio Pulse from Lara Goldstein

June 28, 2023 | 10:27 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.